2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5467 Real-world implementation of glofitamab in R/R B-cell lymphoma: Step-up dosing completion, treatment patterns, and early outcomes

Junfeng Chu, Shuna Yao2, Jiuyang Zhang, MD3, Shuang Zhao, MD4, Zheng Yan, MD5, Haiying Wang, MD6, chao Li, N/A7, Jinxiao Yao8, Ping Wang9, Zhihui Li, MD10, Chunlai Luan11, Zhanfang Wang12, zheng Xu13, Zhihua Yao14, Xinyang Zhao, PhD15, Yanyan Liu, PhD16
1 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
2 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
3 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
4 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
5 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
6 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
7 Nanyang Central Hospital, Nanyang, Henan, China
8 Nanyang Second General Hospital, Nanyang, Henan, China
9 Zhumadian Center Hospital, Zhumadian, Henan, China
10 Xinxiang Central Hospital, Xinxiang, Henan, China
11 Anyang Cancer Hospital, Anyang, Henan, China
12 The First People's Hospital of Pingdingshan, Pingdingshan, Henan, China
13 Xinyang Center Hospital, Xinyang, Henan, China
14 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
15 Kansas University Medical Center, Kansas City, United States
16 Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China

Background: Glofitamab is increasingly utilized in routine practice as monotherapy or in combination with other agents, including chemotherapy, targeted therapies, immunomodulators, and radiotherapy. However, real-world data remain limited regarding treatment patterns, successful step-up dosing (SUD) completion, early treatment failure, and outcomes across diverse lymphoma histologies and high-risk populations. We evaluated treatment delivery, early effectiveness, safety, and prognostic factors in patients receiving glofitamab-based therapies.
Methods: We retrospectively analyzed consecutive patients with relapsed/refractory (R/R) B-cell lymphoma receiving ≥1 dose of glofitamab (SUD protocol) between April 1, 2024, and June 25, 2026. Responses were assessed at cycle 2 (C2) per Lugano criteria. Progression-free survival (PFS) and overall survival (OS) were measured from the first glofitamab dose. Adverse events, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and infections, were evaluated. Unadjusted and multivariable Cox regression analyses were used to identify prognostic factors in patients with aggressive B-cell lymphoma. Data cutoff was August 1, 2026.
Results: The cohort included 135 patients (median age, 58 years [range, 20–82]; 48.9% male; 75.6% stage IV). Histologies comprised DLBCL (n = 105, including 7 with primary and 5 with secondary CNS involvement), high-grade B-cell lymphoma (n = 15; 5 with MYC/BCL2 rearrangements), follicular lymphoma (n = 7), MCL (n = 6), and SLL/CLL (n = 2). Overall, 54.8% and 74.8% of patients met POD12 and POD24 criteria, respectively. 
Patients received a median of 3 glofitamab cycles (range, 0.5–12), either as monotherapy (n = 53) or combination therapy (n = 82). Key combinations included gemcitabine-oxaliplatin (GEMOX) (n = 49), radiotherapy (n = 18), polatuzumab vedotin (n = 10), BTK inhibitors (n = 10), and immunomodulators (n = 9). Notably, 24 patients (17.8%) failed to complete SUD due to early disease progression (n = 7), CRS/ICANS (n = 5), infection (n = 5), or other reasons (n = 7). In multivariable analysis, higher baseline CRP independently correlated with SUD failure (OR, 1.016; 95% CI, 1.003–1.028). Twenty-seven patients received ≥6 cycles. 
At C2, ORR was 51.1% (14 CR, 55 PR) and DCR was 90.4% (53 SD). With a median follow-up of 98 days (range, 5–853), 50 patients progressed and 27 died. Estimated PFS rates at 90, 180, and 365 days were 78.1%, 51.9%, and 41.0%, respectively; corresponding OS rates were 90.1%, 76.6%, and 69.1%. Exploratory analyses indicated prolonged OS with GEMOX-containing (P = 0.035) and immunomodulator-containing (P = 0.037) regimens versus monotherapy.
CRS occurred in 31 patients (23.0%; 6 grade ≥3). ICANS occurred in 4 patients (3.0%; 1 grade ≥3). Infections were noted in 25 patients (18.5%; 5 viral, 5 grade ≥3). No treatment-related deaths occurred.
Among patients with aggressive B-cell lymphoma (n = 120), higher LDH, lower albumin, and higher CRP correlated with shorter PFS and OS in univariable analyses. In multivariable analysis, baseline albumin independently predicted both PFS (HR, 0.92; 95% CI, 0.88–0.97; P = 0.001) and OS (HR, 0.83; 95% CI, 0.77–0.89; P < 0.001), while LDH independently predicted PFS (HR, 1.001; 95% CI, 1.000–1.001; P = 0.032).
Conclusions: In a high-risk, heterogeneous real-world cohort, glofitamab-based regimens demonstrated meaningful early disease control and manageable safety. However, a clinically relevant subset (17.8%) failed SUD completion due to early progression or toxicity. Baseline albumin and LDH emerged as robust independent prognostic factors in aggressive histologies. Longer follow-up and adjusted comparative analyses are warranted to define response durability and optimal combination strategies.

Junfeng Chu: No relevant conflicts of interest to declare.